It only makes sense the oncologists who have the most experience with a certain type of cancer treat patients with that specific cancer more effectively. Mesothelioma is a complicated type of incurable cancer that requires an experienced specialist.
For the record, I don’t like toxic therapy for any type of cancer. At any stage. Unfortunately, toxic chemotherapy can be a necessary evil. Rather, I should say, the right kind of chemo in the right dosages with the right integrative therapies can be the best option for you. After all, chemo and radiaton can fight your cancer yet cause collateral damage to your body.
The study below cites a therapy that may improve the mesothelioma standard.
I am a long-term survivor of an incurable cancer called multiple myeloma. While myeloma is a very different cancer than mesothelioma it is clear to me that these two complicated cancers have a lot in common. If you have been diagnosed with mesothelioma you owe it to yourself to learn about both conventional and evidence-based non-conventional therapies to fight your cancer. You also owe it to yourself to work with a specialist who understands the type of study linked below.
To learn more about those integrative therapies that have proven efficacy of meso killing properties or the ability to enhance the efficacy of specific chemotherapies, scroll down the page, post a question or comment and I will reply ASAP.
Malignant mesotheliomas (MMs) are chemoresistant tumors related to exposure to asbestos fibers. The long latency period of MM (30-40 yrs) and heterogeneity of tumor presentation make MM difficult to diagnose and treat at early stages. Currently approved second-line treatments following surgical resection of MMs include a combination of cisplatin or carboplatin (delivered systemically) and pemetrexed, a folate inhibitor, with or without subsequent radiation. The systemic toxicities of these treatments emphasize the need for more effective, localized treatment regimens.
Targeted therapy (APMS-MB-DOX at 0.05 mg/kg) was more effective than DOX low (0.05 mg/kg) and less toxic than treatment with DOX high (0.2 mg/kg). It also resulted in the reduction of tumor volume without loss of animal health and weight, and significantly decreased tumor cell proliferation. High pressure liquid chromatography (HPLC) of tumor tissue confirmed that APMS-MB-DOX particles delivered DOX to target tissue.
Data suggest that targeted therapy results in greater chemotherapeutic efficacy with fewer adverse side effects than administration of DOX alone. Targeted microparticles are an attractive option for localized drug delivery.”